The post-translational modification of proteins regulates many biological processes. Their
dysfunction relates to diseases. Ubiquitination is one of the post-translational modifications …

Post-translational modifications of cellular substrates with ubiquitin and ubiquitin-like
proteins (UBLs), including ubiquitin, SUMOs, and neural precursor cell–expressed …

The ubiquitin–proteasome system (UPS) comprises a network of enzymes that is
responsible for maintaining cellular protein homeostasis. The therapeutic potential of this …

SUMOylation is a reversible post-translational modification that regulates protein function
through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of …

The proteasome is responsible for selective degradation of proteins. It exists in mammalian
cells under four main subtypes, which differ by the combination of their catalytic subunits: the …

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new
therapeutic approaches are required. One such potential therapeutic strategy is to target the …

E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of
Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in …

The ubiquitin (Ub) and Ub-like (Ubl) protein-conjugation cascade is initiated by E1 enzymes
that catalyze Ub/Ubl activation through C-terminal adenylation, thioester bond formation with …

Ubiquitin (Ub) signaling plays a key regulatory role in nearly every aspect of eukaryotic
biology and is initiated by E1 enzymes that activate and transfer Ub to E2 Ub-conjugating …

Deubiquitinases have emerged as promising drug targets for cancer therapy. The two DUBs
USP25 and USP28 share high similarity but vary in their cellular functions. USP28 is known …